fig7
From: EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
Figure 7. Co-exposure of erlotinib and prexasertib significantly reduced tumor progression in MDA-231 and MDA-468 xenografts. MDA-231 and MDA-468 xenograft containing mice were treated with vehicle, 10 mg/kg BW prexasertib, 50 mg/kg BW erlotinib, or both prexasertib and erlotinib (A); tumor weights at sacrifice for MDA-231 and MDA-468 (B)
